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The combination of ultrasound with nano-
particles enables the development of diﬀer-
ent types of therapeutic strategies. In this
work, we aim to provide an overview of the
main types of inducible responses that have
been reported in the literature in this
context, divided in: inducing drug release,
producing ultrasound-derived biological
eﬀects, modifying nanoparticle biodistribu-
tion and developing theranostic agents.
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Abstract
Ultrasound has attracted much attention in recent years as
an external stimulus capable of activating diﬀerent types of
nanomaterials for therapeutic application. One of the character-
istics that makes ultrasound an especially appealing triggering
stimulus for nanomedicine is its capacity to be non-invasively
applied in a focused manner at deep regions of the body.
Combining ultrasound with nanoparticles, diﬀerent biological
eﬀects can be achieved. In this work, an overview of the four
main types of inducible responses will be provided: inducing
drug release, producing ultrasound-derived biological eﬀects,
modifying nanoparticle biodistribution and developing thera-
nostic agents. Several examples of each one of these appli-
cations are presented here to illustrate the key concepts
underlying recent developments in the discipline.
Keywords: Ultrasound j Nanomedicine j Stimuli-responsive
1. Introduction
Stimuli-responsive nanomaterials for biomedicine have
attracted great attention in recent years. This type of material
can produce diﬀerent responses (commonly involving release
of a drug) when exposed to a certain stimulus.1,2 The triggering
stimulus can be internal, if the pathology of interest is charac-
terized by changes in pH,3,4 redox potential5,6 or presence of
certain enzymes;7 or it can be something externally applied by
the physician, such as light,8­11 magnetic ﬁelds12­15 or ultra-
sound (US).16 In this work, we will focus on US-responsive
nanomaterials and what diﬀerent responses can be engineered
into nanomaterials for biomedicine. In order to be able to
properly describe the progress made in this topic, we will ﬁrst
have to deﬁne some basic concepts related to US and its eﬀects
in biological environments.
US can be deﬁned as an acoustic (mechanical) wave whose
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frequency is above the human hearing limit (20 kHz).8 The US
wave can be deﬁned as a function of various parameters, such
as frequency, power, intensity or pressure. The speed of US
divided by its wavelength results in the frequency, which is the
most common parameter to describe a US wave. The velocity
of the US in water, which is the medium by which it is to be
transmitted in a living organism, is 1480m/s.17 Depending on
its frequency, it can be divided into low frequency US (below
1MHz) or high frequency US (above 1MHz).8 US power can
be expressed in watts (W), although in the clinical environment
the concept of intensity (expressed in W/cm2) is more com-
monly used.18­20 Since it is a mechanical wave, the pressure
generated by the US application is also commonly used to
describe the US conditions applied.21
The use of US in the clinic is widely used for both diagnostic
and therapeutic purposes.22 It has been used for a multitude of
applications, such as the generation of hyperthermia,23 opening
of the blood-brain barrier,24 sonoporation,25 immunostimula-
tion,26 diagnostic imaging27 and physiotherapy,19 among many
others. For its diagnostic use, high frequencies (generally above
3MHz) are usually employed, working at low intensities.28 On
the other hand, for therapeutic application, lower frequencies
are used, generally working at a higher intensity.
The generation of US usually takes place using transducers
constituted by piezoelectric crystals, capable of converting an
electrical signal into a mechanical wave that will be transmitted
by a ﬂuid.16 The use of transducers with curvature allows the
generation of a focal point at a certain distance from the source
of high frequency US. This makes it possible to apply greater
stimulus intensity to the point of interest at a certain depth
within the body in a non-invasive manner, minimizing the
intensity of the US to which the surrounding healthy tissues
will be exposed.23 The ability to focus the US at a certain depth
has led to the development of therapies using high-intensity
focused US (HIFU). The use of HIFU is proposed as an alter-
native to surgery in some cases of internal tumors, by destroy-
ing tissue at the US focal point.28
The high penetration capacity of the US and the possibility
of applying it in a focused manner constitute great advantages
over other widely studied external stimuli, such as light. The
biological eﬀects of US can be divided into thermal eﬀects and
mechanical eﬀects.23 However, it is worth mentioning that both
types of eﬀects will occur simultaneously, and that in most
cases, separating the two is a complex task, as discussed below.
Thermal eﬀects: As a US wave propagates through a tissue,
some of its energy can be absorbed in the form of heat, increas-
ing the temperature in the area.23 Thus, US-generated hyper-
thermia can be used for ablative cancer therapies or to activate
temperature-sensitive nanomaterials.29,30 Thermal eﬀects are
directly related to the frequency of US used: higher frequencies
produce a higher temperature rise when transmitted through
tissues.19
Mechanical Eﬀects: The mechanical eﬀects of the US can be
divided into non-cavitational eﬀects and acoustic cavitation.31
Among the former, the most common is acoustic streaming,
which can be deﬁned as the generation of movement or ﬂow in
a ﬂuid as a result of its exposure to the mechanical waves of
the US.32 Acoustic cavitation, on the other hand, is due to the
interaction of gas bubbles in a ﬂuid with the US mechanical
waves to which it is exposed.33,34 It can be divided into three
stages, resulting in stable cavitation or unstable cavitation (also
referred to as inertial cavitation). First, exposure to mechanical
waves induces the formation of small gas bubbles in the ﬂuid.
The interaction of these microbubbles with US waves causes
them to oscillate in size, expanding and compressing in the
positive and negative pressure phase, respectively (stable cavi-
tation).34 Finally, if the stimulus reaches suﬃcient intensity,
exceeding a threshold size in the negative pressure phase
induces the catastrophic collapse of the same in the positive
pressure phase (inertial cavitation).21 This implosion of the gas
microbubble produces extreme conditions in the local envi-
ronment (at the nanoscale), reaching very high pressures and
temperatures of the order of 5000K, which makes it diﬃcult to
separate thermal and mechanical eﬀects.8 These extreme condi-
tions can result in the generation of light (sonoluminescence)35
and the formation of reactive oxygen species (ROS) due to
pyrolysis of water molecules.31 The mechanical index (MI) is a
parameter that indicates the probability of inertial cavitation in
a ﬂuid exposed to US.36 It is deﬁned as the negative pressure
peak generated divided by the square root of the US frequency
used. MI values greater than 0.7 indicate a high probability of
inertial cavitation. Therefore, the lower the frequency used, the
greater the probability of cavitation.
The generation of cavitation is considered as one of the most
promising applications of the use of US in biomedicine, since
it can generate a great multitude of biological eﬀects. It is
believed to be involved in the permeabilization of the cell
membrane by US (sonoporation),25 and can be used to promote
the penetration of drugs and nanoparticles.21 However, the
pressure required to exceed the cavitation threshold in vivo
may be too great to be used safely without damaging healthy
tissue.36 Therefore, the use of cavitation nuclei capable of
lowering the pressure threshold required to produce acoustic
cavitation appears to be a convenient option for biomedical
application.34 Among the most commonly used cavitation
agents are micrometric lipid bubbles, which are already used in
clinics as US contrast agents,37 submicrometric phase change
droplets38 and submicrometric polymer particles with the abil-
ity to stabilize gas nanobububbles.39,40
Finally, it is worth mentioning that the thermal and mechan-
ical eﬀects of the US, and especially the phenomenon of
inertial cavitation, can be used to accelerate or induce chemical
reactions (sonochemistry).41­46 The induction of chemical reac-
tions in the presence of inertial cavitation may be due to the
generation of reactive oxygen species that initiate a chain of
subsequent reactions, to heating at the nanoscale in the vicinity
of imploding bubbles, to mechanical eﬀects such as acoustic
microstreaming (also associated with cavitation), or to a com-
bination of all these eﬀects.
The US thermal,47 mechanical48 and chemical49 eﬀects can
be used to develop diﬀerent intelligent materials capable of
triggering a response when exposed to stimuli. Thus, lipo-
somes,16,29,50,51 micelles,42,49,52 polymeric particles53 and hybrid
particles54­56 sensitive to US have been developed.
When combining these smart nanomaterials with US appli-
cation, diﬀerent eﬀects can be obtained. The main goal of this
work is not to collect a comprehensive list of all the research
done in US-responsive nanoparticles, but to provide an over-
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view of the main objectives with which US can be employed
in the context of nanomedicine, with some recent examples
presented to illustrate each of the concepts introduced. Accord-
ingly, the main text of the article has been divided into four
sections, corresponding to said objectives: Inducing drug
release, producing US-derived biological eﬀects, modifying
biodistribution and developing theranostic agents (Figure 1).
2. Inducing Drug Release
The most studied triggered behavior in stimuli-responsive
nanomaterials for biomedical application is induced drug
release from nanocarriers.16 US-triggered drug release systems
can be classiﬁed by their type of release proﬁle (single vs
multiple-triggered systems), the type of nanoparticles em-
ployed (liposomes, polymeric nanoparticles, silica nanoparti-
cles, etc), their mechanism of activation (through thermal,
mechanical or chemical eﬀects of US), and their target thera-
peutic application (for example: cancer, pain management, anti-
microbial, rheumatoid arthritis). US-responsive drug carriers
have also been developed in particularly promising areas of
nanomedicine, such as co-delivery of diﬀerent molecules by a
single carrier,57 or delivery of large molecular weight ther-
apeutics.58 The type of release proﬁle desired for a speciﬁc
material is closely related to its target therapeutic application,
since it will depend on factors such as whether the admin-
istration is systemic or local, and the drug pharmacokinetics
and toxicity, among others. Here, we will describe diﬀerent
nanosystems reported in the literature based on their type of
release proﬁle (single or multiple-triggered systems), discus-
sing in each case the target application and the designed acti-
vation mechanism.
When discussing triggerable drug release, two main types
of proﬁles can be distinguished: single-triggered release and
multiple-triggered release. In single-triggered systems, the drug
carrier is found in a closed conﬁguration when administered,
and after a certain lag time, material exposure to a certain
stimulus (like US in the cases shown here) induces an irre-
versible change to an open conﬁguration, which leads to the
complete release of the loaded drug (although this release
process can take a signiﬁcant period of time to be completed).
In multiple-triggered systems on the other hand, the exposure to
the activating stimulus induces the release of only part of the
loaded dose, enabling further triggering events that will each
produce release of the drug. Often, in these systems, the dosage
of released drug can be controlled by modifying the duration
and/or intensity of the triggering stimulus, so in practice, if the
stimulus is intense enough or is applied for a lengthy period of
time, a material with multiple-triggered release capacity can be
employed as a single-triggered system, by forcing the release of
all the loaded drug at once.
2.1 Single-Triggered Drug Release Systems. The main
rationale behind single-triggered drug-release nanosystems is
that controlling the spatiotemporal distribution of free drug
in systemically-administered nanotherapeutics might produce
beneﬁts as both increasing eﬃcacy and reducing undesired
side-eﬀects. This is because preventing premature drug release
during nanocarrier circulation throughout the organism would
limit its action in undesired oﬀ-target organs, thus limiting
dose-limiting toxicities. Then, the possible increase in eﬀective
administered dose in the target tissue could increase its thera-
peutic eﬀect. A clear example of this kind of strategy can be
seen in one of our recent works, where tumor-tropic mesenchy-
mal stem cells were ﬁlled with chemotherapeutic drug-loaded
single-US-triggerable mesoporous silica nanoparticles.56 In this
system, the mesenchymal stem cells would act as vehicles
carrying the drug-loaded nanoparticles towards tumors. How-
ever, this migration process will normally take a few days,
during which the survival of the carrier cells must be ensured.
Premature release of the chemotherapeutic drug doxorubicin
could compromise their viability and migration capacities, so
we introduced a US-responsive gatekeeper on the nanoparticle
surface to prevent it. However, once in the target tumor region,
the maximum possible dose of drug should be released to
produce the maximum possible eﬀect. Therefore, a single-
triggered system was ideal here, which we achieved by using
an irreversible opening mechanism based on a US-induced
reaction that induces a conformation change in the polymeric
gatekeeper employed.
The most eminent example of US-triggered release nano-
systems is probably the use of thermosensitive liposomes in
combination with HIFU to produce the temperature increase.29
These thermosensitive liposomes are obtained by carefully
designing the lipid bilayer so that its transition temperature is
slightly above physiological temperature, and in the hyperther-
mia region. By increasing the surrounding temperature slightly
above the transition temperature of the lipids, a fast release
of the loaded drug is produced. It must be highlighted that
the combination of HIFU with the most clinically-advanced
thermosensitive liposome (Thermodoxμ) is currently under-
going clinical trials, which have so far shown great promise in
this strategy.59 Besides thermosensitive liposomes, many other
nanosystems have been described for the US-induced release
of small molecule drugs, mainly in the context of anticancer
therapy, by designing diﬀerent activation mechanisms that
take advantage of the diﬀerent biological eﬀects of US. As an
example of non-thermosensitive US-responsive liposomes,
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Figure 1. Graphical summary of the parts in which the
present article is divided.
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FSchroeder et al. described a system capable of releasing cis-platin when exposed to low frequency US.50 However, sincelow frequency US is diﬃcult to focus, its use would be limitedto superﬁcial tumors. As we will see below, later works by
other authors have described high frequency-responsive sys-
tems based on diﬀerent activation mechanisms.
After liposomes, polymeric nanoparticles have probably
been the most successful type of US-responsive nanocarriers
for anticancer drug delivery. Among the main examples of this
line of work, we can highlight the pioneering work in which
Xuan et al.52 described a polymeric micelle that could be
activated by HIFU through the induction of a chemical reaction
with one of the monomers employed. The conversion of hydro-
phobic THPMA into hydrophilic methacrylic acid displaced
the lower critical solution temperature (LCST) of the copoly-
mer employed, inducing a conformation change and releas-
ing the drug. We later employed the same strategy to prepare
hybrid polymer-grafted mesoporous silica nanoparticles60 for
anticancer drug release (Figure 2).54­56,61 In a later work, Li
et al. developed another micellar formulation based on block
copolymers obtained by click-chemistry, in which ester bonds
in the junction points of the two blocks are cleaved by HIFU,
releasing a molecule loaded in the core of the micelles.42
Finally, it is worth mentioning that this kind of sonochemical
strategy can be employed to obtain micelle nanocarriers that
can respond to several diﬀerent stimuli, by including the
appropriate chemical moieties in the polymer structure. As an
example of this, Lin et al. developed a triple-responsive block
copolymer that could respond to temperature, US and pH.6
These multiple-stimuli responsive systems provide great design
versatility, enabling ﬁne-tuning the nanocarrier for speciﬁc
therapeutic applications.
US-triggerable drug-releasing formulations can also be
designed to be activated by diﬀerent mechanisms than heat
generation or sonochemistry. For example, Lee et al. devel-
oped a methotrexate-releasing nanosystem based on bursting
gas bubbles generated from a chemical reaction.62 In this
strategy, nanoparticles are ﬁrst used to deliver luminol, which
reacts with ROS in cancer cells generating N2 bubbles. These
gas bubbles are then burst employing US, what induces release
of methotrexate from the folate-conjugated bovine serum albu-
min nanoparticles. Core-shell particles made of mitoxantrone-
encapsulating PLGA coated by liposomes can also be activated
by the mechanical eﬀects of US to release the loaded cargo.63
In the context of non-cancer therapeutic scenarios, Airan
et al. have recently described a nanoemulsion system capable
of releasing propofol when exposed to focused US.64 With this
nanosystem, the authors were capable of inducing therapeutic
eﬀects in an acute rat seizure model by applying extracranial
focused US. On a diﬀerent application, Zhu et al. have recently
reported targeted and PEGylated perﬂuoropentane-based nano-
droplets for dexamethasone delivery in a rheumatoid arthritis
model.65 These particles signiﬁcantly decreased inﬂammation
of joints when employed in combination with US.
2.2 Multiple-Triggered Release Systems. Despite the
many advantages that single-triggered DDS can provide to dif-
ferent therapeutic applications, in many pathological conditions
what would be desirable is the capacity to produce several
drug release events. In such conditions, employing an external
triggering event (such as the application of US) will also enable
adapting the released dose and/or its timing to the changing
needs of the patient. A clear example of this kind of strategy
can also be found in one of our recent publications. In this case,
the chosen application of our DDS was in the context of
perioperative pain management.51 Under this scenario, our goal
was to develop a locally-injectable anesthetic-releasing lipo-
somal formulation that could provide an initial eﬀect that
would take place during the surgical procedure, followed by a
period of time in which the patient could control the amount of
free anesthetic in the area. The main advantage of this kind of
strategy in the clinical setting derives from the common motor
block that is associated to the sensory block produced by local
anesthetics, which for example eliminates the patient’s capacity
to move an aﬀected limb. Providing the patient with control
over the amount of free anesthetic the injected region would
allow them to decide how much pain could be acceptable while
still allowing a certain level of limb movability. To achieve this
goal, we employed liposomes containing both a sonosensitizer
and an unsaturated lipid. When exposed to US, the sonosensi-
tizer would generate reactive oxygen species, which would
induce the peroxidation of part of the unsaturated lipid in the
bilayer, changing its permeability and inducing the release of
part of the loaded anesthetic tetrodotoxin. When combined with
dexmedetomidine-loaded liposomes, a maximum of 5 triggered
anesthetic events could be achieved, even though the duration
of the therapeutic event was reduced with each successive
insonation. More recently, Gao et al. have reported a system
based on multiple-triggerable hollow mesoporous organosilica
nanoparticles capable of releasing bupivacaine when exposed
to US, producing long-lasting analgesia.66
3. Producing US-Derived Biological Eﬀects
The thermal, mechanical and biological eﬀects of US can
be directly used to generate a therapeutic eﬀect in diﬀerent
pathological conditions. The combination of US with nano- or
micro-particles can be used to amplify these eﬀects, improving
therefore the therapeutic eﬃcacy that could be obtained with
US alone.
The most obvious synergy between nano- or micro-particles
and US is to enhance the eﬀect of the mechanical eﬀects of
Figure 2. US-induced ﬂuorescein release from hybrid
mesoporous silica nanoparticles under suspension in PBS
(left) or inside cells in vitro (right). Reprinted with permis-
sion from ref 52. Copyright 2015 American Chemical
Society.
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FUS. Gas-containing of gas-stabilizing materials (such as lipidmicrobubbles, phase-changing nanodroplets and submicro-metric gas-stabilizing particles) can act as cavitation nuclei,decreasing the pressure threshold necessary to achieve acousticcavitation. In this way, some therapeutic eﬀect associated to
cavitation can be achieved at a pressure at which no undesired
eﬀects will be provoked in surrounding non-target tissues. As
a clear example of this strategy, Zhong et al. have recently
described the use of perﬂuorohexane-derived nanodroplets as
thrombolytic agents (Figure 3).67 The CREKA peptide included
in the formulation enabled thrombus targeting, and the appli-
cation of low intensity focused US leads to a robust decrease
in the thrombus burden. Similar sonothrombolysis can be
achieved employing other cavitation nuclei, such as micro-
bubbles.68 In another work, Ishijima et al. showed that after cell
uptake, phase-change nanodroplets were capable of drastically
reducing the necessary pressure threshold to induce cancer cell
death.69
Another potential therapeutic application of US, in this case
by employing its chemical eﬀects, is what has been called
sonodynamic therapy.31 Sonodynamic therapy (SDT, named as
an analogous strategy to photodynamic therapy or PDT) con-
sists in the generation of toxic ROS as a consequence of US
application, and has been proposed in the context of anticancer
and antimicrobial therapies. In general, two components are
needed for SDT: a sonosensitizer and US. A sonosensitizer is a
component that can be excited by US to generate ROS, but it
does not imply any cytotoxic eﬀect in the absence of stimula-
tion.35 The use of nano- or micro-particles for SDT has been
reported to improve its eﬃcacy through various means.70 For
example, improved delivery of sonosensitizer to tumors can be
achieved by taking advantage of the passive accumulation of
sonosensitizer-modiﬁed gold nanoparticles.71 Employing O2
microbubbles carrying a sonsosensitizer could also improve
the eﬃcacy of SDT in hypoxic tumors, since they not only
decreased the pressure necessary to generate cavitation (and
therefore, to activate the sonosensitizer), but also because they
were at the same time providing the oxygen necessary to
generate ROS.72 A similar concept was also developed by Chen
et al., who employed oxygen and sonosensitizer-delivering
hollow mesoporous nanoparticles to improve SDT eﬃcacy.73
Later work also showed the possibility of simultaneously using
the same microbubbles as carriers of anticancer drugs, enabling
combination therapy and enhancing the therapeutic eﬀect.15,74
The work reported by Li et al. also described combined deliv-
ery of sonosensitizer and chemotherapeutic drugs, in this case
employing hollow mesoporous organosilica nanoparticles.75
Nomikou et al. also showed that nanoparticles containing both
a photosensitizer and a sonosensitizer enabled dual PDT-SDT,
which provided enhanced eﬃcacy when compared to both
therapeutic modalities in isolation.76 In the context of anti-
microbial therapy, Pang et al. have recently reported the devel-
opment of bacteria-targeted nanoliposomes that can deliver
high concentrations of sonosensitizer into the target bacteria,
achieving sonodynamic elimination of multidrug-resistant
bacteria.77
4. Modifying Biodistribution
US can also be employed to modify the biodistribution of
nanoparticles, either at the tissue or cellular level. Two param-
eters are fundamental to take into consideration when designing
this kind of strategy: the nanoparticle administration route
(either local/topical or systemic) and the target tissue/cells.
Topical administration of nanoparticles can be considered
when the target area to treat is located in the skin. However,
nanoparticle penetration into the skin tissue after direct admin-
istration on its surface is usually poor.78 US application after
topical administration of nanoparticles provides a mechanical
impulse that drives deeper nanoparticle penetration in the
tissue.78,79 Besides US application, certain nanoparticle char-
acteristics, such as surface charge, were also seen to aﬀect the
penetration capacity of the nanoparticles in skin tissue.78 In
order to further improve this eﬀect, combination of nanopar-
ticles with cavitation nuclei (capable of decreasing the pressure
needed to trigger acoustic cavitation) was shown to enhance the
skin penetration of nanoparticles upon US exposure.80 This
strategy could be employed to deliver nanoparticles to rela-
tively deep areas of the skin, where they could provide a
signiﬁcantly improved therapeutic eﬀect.
In the context of systemically administered nanoparticles,
US has been explored to achieve selective tissue biodistribution
in two broad contexts: to induce selective extravasation of
nanoparticles in desired tissue (mainly in solid tumors) and to
enable nanoparticle crossing the blood-brain barrier (BBB).
Selective nanoparticle extravasation in tumor tissues can
take place due to the enhanced permeability and retention
(EPR) eﬀect. The EPR eﬀect is derived from both a defective
structure in blood vessels irrigating tumor tissue, which makes
them more permeable to macromolecules and nanoparticles,
and collapsed lymphatic vessels, which prevent nanoparticle
withdrawal from tumor tissue after extravasation.81 Even
though the EPR eﬀect has been the main rationale behind nano-
particle use in oncology, its broad applicability in humans has
been questioned.82 Furthermore, even if tumor blood vessels
might be suitable for nanoparticle extravasation, the high inter-
stitial pressure in solid tumors acts as a barrier for eﬀective
extravasation. Generating a certain degree of cavitation (stable
or inertial) could provide an additional force to extravasate the
nanoparticles instead of relying merely on passive diﬀusion,34
and it could also enhance the penetration depth of the nano-
particles in tumor tissue.83 This concept has been successfully
Figure 3. Conceptual representation of the use of phase-
change perﬂuorohexane-derived nanodroplets for US-
induced thrombolysis. Reprinted with permission from
ref 64. Copyright 2019 American Chemical Society.
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developed to various degrees in in vitro or in vivo models with
viruses,84 liposomes,85 polymeric nanoparticles,86,87 gold nano-
particles88 and mesoporous silica nanoparticles89 (Figure 4).
In order to achieve the level of acoustic cavitation that is
necessary to enable nanoparticle extravasation without damag-
ing the surrounding healthy tissues, diﬀerent cavitation nuclei
can be employed to decrease the necessary pressure threshold.
Recently, Mannaris et al. compared the eﬀect at various fre-
quencies of diﬀerent cavitation nuclei in this context: micro-
bubbles, nanodroplets and polymer gas-stabilizing nanoparti-
cles.90 The authors found that deeper and more directional
extravasation took place at higher frequencies, and that poly-
meric gas-trapping produced the most extensive extravasation
for the same applied energy.90 In all these works, a mixture of
the therapeutic nanoparticle and the cavitation nuclei has to be
administered in order to provide both the cavitation-generation
capacity and the desired therapeutic eﬀect. However, recent
investigations by diﬀerent groups have also begun exploring
combining both components in a single structure. In that way,
Su et al. have recently described similar polymeric gas-
stabilizing microstructures with multiple gas-stabilizing cav-
ities per particles.91 In this case, the nanoparticles were made of
poly(lactic-co-glycolic acid) and included within the polymeric
network a rhodamine dye as a model for small molecule drugs.
After showing their potential for inducing their remote implan-
tation by application of HIFU, the authors also conﬁrmed the
sustained release of the loaded ﬂuorophore over time.91 Other
recent examples showing combination of the cavitation nuclei
and therapeutic nanoparticle functions can be found in the work
of Papa et al. who employed nanoparticle aggregates that
trapped gas within the aggregate and could be dispersed into
individual particles while generating cavitation,53 and in the
work by Lv et al. who included mesoporous silica nano-
particles within microbubbles for this same purpose.92
A limiting factor for the treatment of pathologies of the
central nervous system (CNS) is the blood-brain barrier (BBB).
The BBB is a restrictive barrier that prevents most toxic (and
therapeutic) agents from reaching the CNS.93 The physical
structure of the BBB relies on tight junctions present between
specialized endothelial cells. This structure can be reversibly
impaired by the generation of focused acoustic cavitation in the
region, temporarily enabling the delivery of certain therapeutics
to the CNS. The translation of this type of strategy to the clinic
could enable using a wide variety of therapeutic agents for
diﬀerent CNS pathologies which might not be suitable today
due to biodistribution limitations. So far, diﬀerent preclinical
studies have shown the possibility of using US to enable deliv-
ery to the CNS of diﬀerent nanotherapeutic agents, including
nanoparticles for gene therapy,94,95 magnetic nanoparticles,93,96
gold nanoparticles,97­99 polymeric nanoparticles100 and lipo-
Figure 4. In vitro mesoporous silica nanoparticle delivery in an agarose gel model at diﬀerent US exposure conditions. Reprinted
with permission from ref 86. Copyright 2018 Elsevier.
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somes.101 It is worth mentioning that, as was also the case in
the previous section, in order to decrease the pressure threshold
needed to trigger cavitation up to a safe level for surrounding
tissues, diﬀerent cavitation nuclei must be used to enable
successful reversible opening of the BBB for nanoparticle
delivery. The most widely used agents for this purpose are
microbubbles, which can be co-injected with the therapeutic
nanoagent98,101,102 or complexed directly with them, having
both components (therapeutic agent and cavitation nuclei) in a
single structure.103 Some work employing other cavitation
nuclei has also been reported, such as using nanobubbles in the
context of SNC gene therapy.95
Finally, once the nanoparticles are located in the desired
tissue or organ, it might be the case that, in order to maximize
the therapeutic eﬀect, nanoparticle uptake by the target cells
is necessary. US can also be used here to trigger nanoparticle
uptake by nearby cells, through diﬀerent mechanisms. For
example, the direct eﬀect of US on the cell membranes can be
used to ease nanoparticle introduction within the cell cyto-
plasm, in a process usually called sonoporation.104,105 Another
option to achieve a similar goal would be developing US-
responsive hierarchical targeting strategies. In hierarchical
nanoparticle targeting, an uptake-inducing moiety is exposed
on the nanoparticle surface after a certain environmental condi-
tion is present. Following this line of work, we have recently
reported the possibility of employing positively-charged nano-
particles that have been PEGylated through a thermosensitive
linker.106 The presence of PEG chains on the nanoparticle
surface provide stealth capabilities and physically hide the
positively-charged amino groups on the nanoparticle surface.
Upon US exposure, localized heating produces the de-
PEGylation of the nanoparticles, exposing their positive sur-
face charge and inducing nanoparticle uptake due to electro-
static interaction of the nanoparticles with the cell membrane.
Even though for now this strategy has only been presented as a
proof-of-concept, further developments in this direction could
be very promising for novel therapeutics.
5. Developing Theranostic Agents
US-based imaging is widely used in clinical practice, and
echogenic contrast agents (such as microbubbles) can be
employed to improve its performance.51 By combining these
imaging capacities with therapeutic carriers, theranostic agents
can be developed. This allows, for example, ensuring the cor-
rect injection of an US-triggerable (and echogenic) anesthetic
micron-sized liposomal formulation around the desired nerve
(Figure 5).51
Diﬀerent types of formulations have been developed as
therapeutic agents that simultaneously act as US contrast
agents, such as phase-change nanodroplets,107­110 silica nano-
particles111 and multilayer capsules.112 In this way, US imaging
can be used to follow nanoparticle accumulation in the target
area (for example, by EPR-driven tumor accumulation) and
also to trigger drug release when suﬃcient amount of the thera-
peutic nanoagent has been detected in the region to treat.109 US
Contrast agents can not only be developed in combination with
drug-delivery carriers, but also with agents employed for some
of the other therapeutic modalities that we have already dis-
cussed here, such as generation of inertial cavitation and SDT.
As an example of this, Feng et al.113 developed pH/US dual-
responsive gas-generating nanoparticles carrying a sonosen-
sitizer to combine in one single nanostructure US imaging,
generation of inertial cavitation and SDT capacities.
6. Conclusion
The development of ultrasound-activated nanomaterials for
biomedical application is an extremely active ﬁeld of research
that holds great promise for creating future therapeutic strat-
egies. Among the main examples discussed here, ultrasound
has not only been employed to trigger drug release from
nanoparticles, but also to produce direct biological eﬀects in
combination with nanostructures, to modify nanoparticle bio-
distribution and to develop theranostic agents. While some
work has already been done in combining those strategies,
future work will surely delve deeper into strategies that em-
ploy several or all of these eﬀects simultaneously. From these
combined approaches remarkable synergies can appear, such
as employing the feedback from theranostic systems to select
the optimal time to trigger drug release, or even to further
exploit the eﬀect of triggered drug release by combining it with
direct biological eﬀects produced by the US stimulus. Further
improvements can also be achieved by combining ultrasound-
responsive materials with other stimuli-responsive nanostruc-
tures, both for therapeutic and imaging purposes.114,115 In this
way, the advantages of diﬀerent stimuli can be seized to
achieve their combined full potential. Finally, we believe that
through the development of all of the recent advances men-
tioned here, the ﬁeld of ultrasound-responsive nanomaterials
has reached a level of maturity that should now enable these
technologies to become closer to the clinical setting. In order
to reach the clinic, successful nanostructures should have a
simple, reproducible and scalable production process, what can
constitute a signiﬁcant challenge for many of the chemically
complex nanosystems here presented. On the other hand, the
widespread use of diagnostic ultrasound in hospitals as well as
therapeutic ultrasound in physiotherapy and other applications
could also accelerate the adoption of these strategies compared
to the use of other external stimuli.
This paper was funded by the European Research Council
(Grant VERDI; ERC-2015 AdG no. 694160). JL Paris is sup-
ported by a post-doctoral fellowship from the Ramón Areces
Foundation.
Figure 5. Sonograms before and after US-guided perisci-
atic injections of a liposomal formulation for anesthesia
application. Reprinted with permission from ref 49. Copy-
right 2017 Springer Nature.
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